aforesaid proteins that is so called a u201c cocktail u201d vaccine of the present invention in another embodiment of the present invention said active ingredient may comprise an amino acid sequence of seq id no 08 seq id no 09 seq id no 10 seq id no 11 seq id no 12 seq id no 13 seq id no 14 or a combination thereof in an alternative embodiment as long as the antigenic determinant formed by folding of a peptide of said amino acid sequence is not interfered said active ingredient may be a fusion protein with at least two said sequences in another alternative embodiment said active ingredient comprises two or more proteins respectively comprising one of the aforesaid amino acid sequences that is so called a u201c cocktail u201d vaccine of the present invention said pharmaceutically acceptable adjuvant is used for improving the immune effect of said active ingredient stabilizing said active ingredient and or increasing the safety of vaccines said pharmaceutically acceptable adjuvant of the present invention includes but not limits to a complete freund 39 s adjuvant an incomplete freund 39 s adjuvant an alumina gel a surfactant a polyanion adjuvant a peptide an oil emulsion or a combination thereof the vaccine of the present invention may have one or at least two said active ingredients i e a cocktail vaccine in an example of the present vaccine said active ingredient is of a concentration of 50 to 3500 u03bcg ml based on the total volume of said vaccine in a preferable embodiment of the present invention when said vaccine.